Back

Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy

29 August 2025 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Cardiac amyloidosis (1) Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Miss P. Domenech (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Assistant Professor A. Zaroui (Creteil, FR)
Abstract Slides Video
Presentation thumbnail
Doctor A. Martins (Leiria, PT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Cardiac amyloidosis (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
thumbnail
Congress Presentation
Factors associated with improved survival in patients with wild-type transthyretin amyloid cardiomyopathy on tafamidis therapy
thumbnail
Congress Presentation
Characteristics and treatment of contemporary real-world patients with cardiac transthyretin amyloidosis: a retrospective, multicenter, observational study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources